
Glenmark inks $18 million deal for cancer drug with China’s Hengrui
Glenmark Pharmaceuticals Ltd on Wednesday announced a licensing deal with Chinese drugmaker Hengrui Pharma for its under-development lung and breast cancer drug. The deal involves an upfront payment of $18 million, followed by regulatory and commercial …